BACKGROUND: Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. MATERIALS AND METHODS: We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). RESULTS: In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. CONCLUSION: Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
BACKGROUND: Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. MATERIALS AND METHODS: We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). RESULTS: In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. CONCLUSION:Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
Authors: Santiago Moragon; Cristina Hernando; Maria Teresa Martinez-Martinez; Marta Tapia; Belen Ortega-Morillo; Ana Lluch; Begoña Bermejo; Juan Miguel Cejalvo Journal: Cancers (Basel) Date: 2022-06-28 Impact factor: 6.575
Authors: Erika Hamilton; Kimberly Blackwell; Amy C Hobeika; Timothy M Clay; Gloria Broadwater; Xiu-Rong Ren; Wei Chen; Henry Castro; Frederic Lehmann; Neil Spector; Junping Wei; Takuya Osada; H Kim Lyerly; Michael A Morse Journal: J Transl Med Date: 2012-02-10 Impact factor: 5.531
Authors: Eliza Guti; Zsolt Regdon; Isotta Sturniolo; Alexandra Kiss; Katalin Kovács; Máté Demény; Árpád Szöőr; György Vereb; János Szöllősi; Csaba Hegedűs; Zsuzsanna Polgár; László Virág Journal: Cancer Immunol Immunother Date: 2022-01-23 Impact factor: 6.630
Authors: Debora Fumagalli; David Venet; Michail Ignatiadis; Hatem A Azim; Marion Maetens; Françoise Rothé; Roberto Salgado; Ian Bradbury; Lajos Pusztai; Nadia Harbeck; Henry Gomez; Tsai-Wang Chang; Maria Antonia Coccia-Portugal; Serena Di Cosimo; Evandro de Azambuja; Lorena de la Peña; Paolo Nuciforo; Jan C Brase; Jens Huober; José Baselga; Martine Piccart; Sherene Loi; Christos Sotiriou Journal: JAMA Oncol Date: 2017-02-01 Impact factor: 31.777
Authors: Denis M Collins; Stephen F Madden; Nicola Gaynor; Dalal AlSultan; Marion Le Gal; Alex J Eustace; Kathy A Gately; Clare Hughes; Anthony M Davies; Thamir Mahgoub; Jo Ballot; Sinead Toomey; Darran P O'Connor; William M Gallagher; Frankie A Holmes; Virginia Espina; Lance Liotta; Bryan T Hennessy; Kenneth J O'Byrne; Max Hasmann; Birgit Bossenmaier; Norma O'Donovan; John Crown Journal: Clin Cancer Res Date: 2020-10-29 Impact factor: 13.801